Johann Von Felden

Hamburg, HH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 92 publications

Extended longitudinal validation of serum procalcitonin as a biomarker for fibrolamellar hepatocellular carcinoma.

Extended longitudinal validation of serum procalcitonin as a biomarker for fibrolamellar hepatocellular carcinoma.

Journal: Journal of hepatology

Published: April 13, 2026

Predicting Decompensation in Unresectable Hepatocellular Carcinoma on Atezolizumab Plus Bevacizumab: The ARTE Score.

Predicting Decompensation in Unresectable Hepatocellular Carcinoma on Atezolizumab Plus Bevacizumab: The ARTE Score.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: February 13, 2026

Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 28, 2025

Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC.

Circulating extracellular vesicles carrying PD-1, PD-L1 and CTLA-4 inform resistance to anti-PD-L1-based therapy in HCC.

Journal: Gut

Published: November 21, 2025

TGF-β1 and TGF-β2 family members differentially modulate tumor initiation and invasiveness of primary liver cancer in a MMP14-dependent manner.

TGF-β1 and TGF-β2 family members differentially modulate tumor initiation and invasiveness of primary liver cancer in a MMP14-dependent manner.

Journal: Carcinogenesis

Published: October 24, 2025

A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.

A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.

Journal: Journal of hepatology

Published: September 04, 2025

A dual compartment peripheral blood signature of soluble and membrane-bound immune checkpoints predicts outcome in lymphoma patients.

A dual compartment peripheral blood signature of soluble and membrane-bound immune checkpoints predicts outcome in lymphoma patients.

Journal: Oncoimmunology

Published: August 28, 2025

Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study.

Lenvatinib vs. sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN study.

Journal: JHEP reports : innovation in hepatology

Published: May 06, 2025

Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass).

Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass).

Journal: Therapeutic advances in medical oncology

Published: March 31, 2025

Endoscopic findings of Bouveret syndrome.

Endoscopic findings of Bouveret syndrome.

Journal: Zeitschrift fur Gastroenterologie

Published: March 31, 2025

Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab.

Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab.

Journal: Annals of hepatology

Published: January 22, 2025

Bile acid retention in efferocytic macrophages shapes their inflammatory status during cholangitis.

Bile acid retention in efferocytic macrophages shapes their inflammatory status during cholangitis.

Journal: The Journal of experimental medicine

Published: November 05, 2024

Showing 1-12 of 92

Last Updated: 09/26/2026